6 January 2021 in Neurological Research
NMNataša Dragašević Mišković
Nataša Dragašević Mišković
+5
Introduction: Although one of the most common monogenic late-onset neurodegenerative disorders, fragile-X-associated tremor/ataxia syndrome (FXTAS) is still underdiagnosed. The aim of the present study was to estimate the frequency of premutation carriers in patients with unexplained degenerative ataxias, action tremor or parkinsonism, and action tremor with or without associated cognitive impairment. Methods: The study comprised 100 consecutive patients with the disease onset >49 years who had any form of unexplained action tremor, cerebellar ataxia, followed by parkinsonism with or without incipient dementia, and in whom the FMR1 repeats size was determined. Results: Premutation in the FMR1 was identified in two patients (2%): the first, male patient had 83 CGG repeats and the second, female patient had 32 and 58 CGG repeats. Discussion/Conclusion: FXTAS was relatively rare among older patients with unexplained ataxia and action tremor, with or without parkinsonism and/or cognitive impairment. Tremor and ataxia were major clinical features in our two patients, although parkinsonism, autonomic dysfunction and psychiatric problems might be an important part of the spectrum. Probable FXTAS should be considered in the differential diagnosis of patients with unexplained action tremor and ataxia, and undetermined parkinsonism, especially when there was a positive family history for involuntary movement disorders in other family members and/or autism spectrum disorders in younger cousins.
1 January 2023 in Medicinska istrazivanja
Introduction: Alzheimer's disease (AD) is a chronic neurodegenerative disease, which is clinically manifested by the development of dementia. Studies of genetic susceptibility to AD indicate a whole range of genes and their variants that can potentially influence an individual's susceptibility to develope the disease. AD17 represents a form of Alzheimer's disease associated with mutation(s) in the TREM2 gene, encoding triggering receptor expressed on myeloid cells 2. The aim of this study was to determine the frequency of R47H variant of the TREM2 gene in the population of AD patients, to compare the frequency of the variant in the population of AD patients and the control group, and to determine a possible association of a certain genotype with susceptibility to AD. Material and Methods: The study included 168 consecutive patients with AD and 190 healthy controls. The clinical inerview, neurologic examination, and neuropsychological set of cognitive assessment were performed by neurologists and neuropsychologists in expertise with neurodegenerative deseases. Genotyping of rs75932628, R47H polymorphism of the TREM2 gene was performed using Real-time Polymerase Chain Reaction and TaqMan® SNP genotyping assay (Applied Biosystem by Thermo Fisher Scientific, USA) according to the manufacturer's recommendations. Results: In the group of AD patients the frequency of C allele was 98.8%, while the T allele was present in 1.2% of patients. The frequency of the T allele was statistically significantly higher among the AD population than among the control group (p<0.05). The frequency of homozygotes without mutation (CC genotype) was 97.62%, while the frequency of heterozygotes for the mutation (CT genotype) was 2.38% among patients with AD, and the frequency of homozygotes without mutation (CC genotype) was 100% among healthy controls. Conclusion: Our study indicated a possible association of the heterozygous form of the R47H variant of TREM2 gene with the susceptibility for the deve-lopement of AD in Serbian population.
5 October 2026 in Clinical Neuropharmacology
Objectives: Thrombolytic therapy with Alteplase is the standard treatment for eligible patients with acute ischemic stroke, but clinical response and hemorrhagic complications vary considerably among patients. This study aimed to investigate whether selected polymorphisms within the MMP-8 and MMP-9 genes are associated with baseline stroke severity, functional recovery, and hemorrhagic complications after thrombolytic therapy. Materials and Methods: Over a 24-month period, 166 Caucasian patients with acute ischemic stroke treated with intravenous Alteplase were prospectively enrolled. Genotyping was performed for MMP-9 rs3918241 and rs3918249, and MMP-8 rs1940475 and rs11225395 polymorphisms. Associations with neurological severity, functional outcome, and postthrombolytic hemorrhagic complications were analyzed. Haplotype analysis was performed for the investigated MMP-8 and MMP-9 variants. Results: No significant associations were observed between the investigated MMP-9 polymorphisms and functional recovery or hemorrhagic complications after Alteplase treatment. However, carriers of the MMP-9 rs3918249 T allele had lower National Institutes of Health Stroke Scale scores at admission, suggesting a less severe initial clinical presentation. For MMP-8 , patients who developed symptomatic intracerebral hemorrhage were significantly more likely to carry the rs1940475 TT genotype ( P = 0.032; odds ratio = 5.10; 95% CI: 1.27-20.56). Haplotype analysis showed strong linkage disequilibrium between rs1940475 and rs11225395, and the TG haplotype was significantly more frequent in patients without hemorrhagic transformation than in those with hemorrhagic transformation. Conclusions: The investigated MMP-9 polymorphisms were not associated with postthrombolytic recovery or hemorrhagic complications. In contrast, MMP-8 rs1940475 and MMP-8 haplotypes may be related to hemorrhagic risk after Alteplase therapy.